buyNotable cluster of 5
Richard A Barasch bought $1.4M of STLN
director at Oncology Institute, Inc.. 1,358,448 shares at an average of $1.04, traded Mar 26, 2025, filed Mar 28, 2025.
Conviction score
65Value
$1.4M
1,358,448 shares
Holdings after
1,775,641
+326% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$1.4M at market
- +10Relative to holdingsHoldings up 326%
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001079973-25-000513, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2025 | POpen-market purchase Common Stockindirect: By LLC | +1,358,448 | $1.04 | $1.4M | 1,775,641 | Mar 28, 2025 |
| Mar 26, 2025 | POpen-market purchase Common Warrantderivativeindirect: By LLC | +679,224 | $0.13 | $85k | 679,224 | Mar 28, 2025 |
Related signals
Other insiders at Oncology Institute, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Oncology Institute, Inc. | Robert Ross Carter Chief Financial Officer | $9,434 9,056 shares | +30% | |
| 38Weak | Oncology Institute, Inc. | Jeremy Castle Chief Operating Officer | $9,434 9,056 shares | +11% | |
| 30Weak | Oncology Institute, Inc. | Brad Hively director | $9,434 9,056 shares | +1% | |
| 42Moderate | Oncology Institute, Inc. | Karen Marie Johnson director | $38k 36,224 shares | +22% | |
| 32Weak | STLNbuy Oncology Institute, Inc. | Brad Hively director | $50k 300,000 shares | +82% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.